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Abstract 
Mitochondrial (mt) diseases are devastating neurodegenerative pathologies due to mutations in 
nuclear or mt genes. Among mtDNA pathogenic mutations, more than one half has been identified 
in transfer RNA (tRNA) genes. These are responsible for a wide range of pathologies including 
myopathies, encephalopathies, cardiomyopathies and deafness for which no effective treatment is 
available at present. Therefore, new strategies to suppress their damaging effects are required to 
envisage therapeutic approaches for these diseases. Here we report data for carbon nanotubes 
(CNTs) derivatives showing that the conjugates bearing a specific peptide sequence are able to 
target the mitochondria in yeast and human monocyte cells while the control derivative without the 
peptide diffuses into cytoplasm. Moreover the compounds do not affect cellular viability and 
cytotoxicity both in vitro and in vivo. Toxicity of the constructs is also assessed on the simple 
pluricellular model Caenorhabditis elegans. 
 
Key words: mitochondrial diseases, tRNA mutations, suppressor genes, intracellular delivery, 
carbon nanotubes, nanomedicine 
 
Abbreviations: mt, mitochondrial; bp, base-pair; aa, amino acids; aaRS, aminoacyl-tRNA 
synthetase; CNTs, carbon nanotubes; MWCNTs, multi-walled carbon nanotubes; LDH, lactate 
dehydrogenase; PBMCs, peripheral blood mononuclear cells; LPS, lipopolysaccharide; DAPI, 4',6-
diamidino-2-phenylindole; FITC, fluorescein isothiocyanate. 
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Introduction 
Currently different strategies such as those aimed at mt tRNA delivery or mt ATP increased 
production have been proposed for treatment of respiratory chain deficiencies especially due to 
mutations in mt tRNA genes. Nevertheless, at present, no treatments or therapies have been 
successfully utilized. 
Based on the evidences provided so far, sequences derived from the carboxy-terminal domain of 
human mt LeuRS (LeuRS-Cterm) are an attractive new candidate for future therapeutic applications 
in mt tRNA related diseases and open a number of potential additional therapeutic approaches. 
Studies on the yeast model revealed that overexpression of the nuclear genes coding for the mt 
aaRS 1,2,3,4,5 rescued the growth-defective phenotype of strains carrying human equivalent point 
mutations in the cognate mt tRNAs 1. 
The results obtained in the yeast model have been paralleled in human cell lines, 6,7,8,9 and we 
demonstrated that human mt LeuRS-Cterm is the region necessary and sufficient to suppress the mt 
defects of mutants in both cognate and non-cognate mt tRNAs (namely tRNALeu(UUR), tRNAIle, 
tRNAVal, all of which are aminoacylated by Class Ia aaRSs) with higher rescuing activity than the 
whole mt LeuRS 10,11. 
Moreover we have previously demonstrated that the yeast mt LeuRS-Cterm was endowed with mt 
targeting activity 5. We have also identified the minimal sequences of the mt LeuRS-Cterm 
responsible for suppression. The short isolated peptides of 15 and 16 amino acids (named β30_31 
and β32_33) were endowed with the same suppressing activity of the full Cterm when 
overexpressed in a broad range of different yeast mt tRNA mutants 5,12. In vitro experiments 
demonstrated that mt LeuRS-Cterm peptide was able to directly and specifically interact either with 
human cognate mt tRNALeu(UUR) either with non-cognate mt tRNAIle even if with 4-fold lower 
affinity 11. Moreover we have shown that the β30_31 peptide specifically interacts with cognate and 
non-cognate mt tRNAs 5,13. The demonstration that the catalytic function of mt LeuRS is not 
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required for rescuing activity and that the interaction occurring between the mt LeuRS-Cterm 
domain and the cognate or non-cognate tRNA in in vitro shift binding experiment 5 strongly point 
to a ‘chaperone-like’ molecular effect. We hypothesized that the interaction of the overexpressed 
sequences with the mutated mt tRNA stabilizes the native-like tRNA structure which would better 
establish interactions with other macromolecular partners required for mt protein synthesis, and/or 
arises less susceptible to degradation events. 
 
In recent years the mt targeting has been proposed as a new therapeutic approach for mt 
dysfunction-related diseases. At present highly active compounds have been identified; however, 
the enormous challenge that should be overcome is mainly due to the difficult road that these 
molecules have to take for mt entrance from the cellular surface. This way is further complicated 
because the extremely complex nature of the mitochondria themselves. 
Over the last decade, nanotechnology has been extensively introduced into biomedical applications, 
including biological detection, drug delivery, diagnostic imaging, and tissue engineering 14. 
Nanotechnology based delivery vehicles provide numerous advantages to increase the therapeutic 
activities of small molecules 15.  
CNTs are a very promising nanomaterial and there are many studies on their possible application as 
scaffold for tissue regeneration, biosensors and drug vectors 16,17. The characteristics that render 
them so interesting are ranging from their peculiar one dimension structure to their electronic 
properties. From the structural point of view, CNTs can present one or many concentric walls 
(single and multi-walled CNTs, SWCNTs and MWCNTs, respectively), and they can vary in 
diameter, chirality and length. Their tendency to aggregate can be overcome by chemical 
functionalization, which can be non covalent or covalent. These two approaches result in different 
pros and cons, in fact while in the first case the electronic characteristics of CNTs are preserved 
without the disruption of the aromatic system, the second approach changes the hybridization of the 
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carbon atoms from sp2 to sp3. However, the covalent derivatization leads to more stable systems in 
which the introduced functionalizations cannot be easily detached from the surface. Another 
difference that plays an important role in the biological application of CNTs is due to the different 
internalization mechanism depending on the functionalization pattern. CNTs in fact are able to enter 
the cells both via an energy-dependent, endosomally mediated internalization mechanism 18 and via 
direct translocation through the plasma membrane into the cytoplasm 19,20. Between the two 
possible pathways of internalization, the nature of the functionalization of nanotubes seems to be of 
great importance. Indeed, the presence of biomacromolecules such as proteins, antibodies, DNA or 
phospholipidic structures supramolecularly linked on the nanotube surface has been associated with 
energy-dependent endocytotic uptake 18. It means that, the direct conjugation of short peptides on 
the CNTs surface could allow the direct internalization of the system, escaping the endosomal 
pathway and surviving the lisosomal destiny. The potential benefits of integrating nanomaterials 
based on carbon nanotubes have been recently engineered to target mitochondria 21,22. 
 
Here we test the mt delivery activity of MWCNTs conjugated with the short peptide of 16 amino 
acids (β32_33) derived from the Cterm of human mt LeuRS. Fluorescence microscopy shows mt 
localization in yeast and human monocyte cells for these constructs, while the control without the 
peptide β32_33 is diffused in the cytoplasm; when the peptide is conjugated the mt targeting 
activity is improved at least in monocyte cells. Moreover, Caenorhabditis elegans lifespan and 
fertility are not affected by CNTs treatments. 
 
Experimental 
Synthesis of CNTs 
The peptides with and without FITC have been purchased from CRIBI (Centro di Biotecnologie – 
University of Padova). In the suppressive sequence, a cysteine residue at the N-terminus has been 
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introduced to allow the so-called thiol-Michael addition click reaction on the nanotubes, properly 
bearing maleimide units. Analogously a lysine-FITC residue was added at the C-terminus, to 
introduce a fluorescent dye on the peptides itself. So the used peptides are: 
CKKSFLSPRTALINFLVK(FITC)-OH and CKKSFLSPRTALINFLV-OH. 
Materials and Reagents: Pristine multi-walled carbon nanotubes (p-MWCNTs) were acquired from 
Nanostructured & Amorphous Materials (Lot. #1237YJ). According to the manufacturer, the p-
MWCNTs had a purity of >95%, 20-30 nm external diameter, internal diameter 5-10 nm, 0.5-2 µm 
length, specific surface area of 110-130 m2/g and density of ~2.1 g/cm3. All other reagents were 
purchased from Sigma Aldrich, TCI, Fluorochem or Carlo Erba and were used without further 
treatments. Membrane filters were 47 mm diameter / 0.45 µm pore size hydrophilic PTFE sheets 
from Merck-Millipore commercial source (Omnipore® JHWP04700). In order to perform the 
Kaiser Test, a commercial kit containing the necessary solutions was employed (Sigma Aldrich 
60017-1EA). 
Characterization Techniques: Thermogravimetric analyses (TGA) were recorded on a TGA Q500 
(TA instruments) under a flow of N2 (90 mL min-1) following a temperature program with an 
isothermal at 100°C for 20 min, followed by a ramp of 10°C min-1 to 700°C. The samples ranged 
from 1 to 2 mg, precisely weighed. TGA analyses and derivatives of all compounds are shown in 
Fig. S1. Fluorescence measurements were performed on a Cary Eclipse (Agilent Technologies) 
fluorescence spectrophotometer using quartz cuvettes with a path length of 1 cm. Kaiser Test was 
applied to functionalized MWCNTs through the experimental procedure reported elsewhere 23. The 
UV/Vis-NIR spectroscopic measurements implied in this analysis were carried out on a Varian 
Cary 5000 spectrophotometer using polystyrene cuvettes with a path length of 1 cm. Syntheses of 
amino acids 1 24 and 2 25 were performed as already reported in literature. 
Functionalization of MWCNTs: f-MWCNT 1: 90 mg of p-MWCNTs (1 eq, ~ 7.5 mmol C) in 90 
mL of o-dichlorobenzene through bath sonication for 10 min. The suspension was brought to 180ºC 
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under constant magnetic stirring and then 180 mg of the N-Phth α-amino acid 1 (0.072 eq, 0.54 
mmol) and 80 mg of paraformaldehyde (0.35 eq, 2.6 mmol). The reaction mixture was left stirring 
at 180ºC for 2 h, then it was cooled down to room temperature and another 180 mg of 1 and 80 mg 
of paraformaldehyde were added, while applying 5 min of bath sonication. This systematic was 
repeated up to a total of five times, every two hours. Afterwards, the reaction medium was left at 
180ºC under magnetic stirring until completion of 24 h from the start. The medium was again 
cooled down to room temperature and vacuum-filtered over Omnipore® membrane and copiously 
washed with N,N’-dimethylformamide (DMF). The solid cake was re-dispersed in DMF by aid of 
bath sonication, and the filtration process was repeated enough times to eventually obtain a 
colourless filtrate. Then, the same filtration was repeated a couple of times with MeOH and finally 
rinsed with diethyl ether and dried under vacuum. Obtained mass: 93 mg. Functionalization degree: 
372 µmol/g (TGA); 150 µmol/g (Kaiser Test after deprotection). 
f-MWCNT 2: 90 mg of f-MWCNT 1 (1 eq, ~ 7.5 mmol C) were dispersed in 90 mL of DMF with 
bath sonication for 10 min. The suspension was brought to 120ºC under constant magnetic stirring 
and then 180 mg of the N-Boc α-amino acid 2 (0.079 eq, 0.59 mmol) and 80 mg of 
paraformaldehyde (0.35 eq, 2.6 mmol). The reaction mixture was left stirring at 120ºC for 2 h, then 
it was cooled down to room temperature and another 180 mg of 2 and 80 mg of paraformaldehyde 
were added, while applying 5 min of bath sonication. This systematic was repeated up to a total of 
five times, every two hours. Afterwards, the reaction medium was left at 120ºC under magnetic 
stirring until completion of 24 h from the start. The medium was again cooled down to room 
temperature and vacuum-filtered over Omnipore® membrane and copiously washed with DMF. 
The solid cake was re-dispersed in DMF by aid of bath sonication, and the filtration process was 
repeated enough times to eventually obtain a colourless filtrate. Then, the same filtration was 
repeated a couple of times with MeOH and finally rinsed with diethyl ether and dried under 
vacuum. Obtained mass: 88 mg. Functionalization degree: 25 µmol/g (TGA), 37 µmol/g (Kaiser 
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Test after selective deprotection of the Boc protecting group). 
f-MWCNT 3: 80 mg of f-MWCNT 2 were dispersed in a hydrazine monohydrate solution of 65% 
in ethanol (1 mL in 80 mL EtOH). The medium was kept under stirring for 24 h at room 
temperature. The obtained product was vacuum-filtered and washed with Milli-Q water until the 
falling waters presented neutral pH. To favour the removal of hydrazine leftovers, while keeping the 
Boc group unharmed, the first aliquot of washing water was slightly acidified with one droplet of 
HCl 4M. The solid cake over the filter was rinsed with MeOH and Et2O and was left to dry under 
vacuum. Obtained mass: 77 mg. Functionalization degree: 360 µmol/g (free amine from TGA); 105 
µmol/g (Kaiser Test). 
f-MWCNT 6: 30 mg of f-MWCNT 3 (3 µmol of free amine groups, according to Kaiser Test) 
were dispersed in 30 mL of anhydrous DMF and the mixture was bath-sonicated for 20 min, while 
keeping an argon balloon connected. Then 80 mg of N-succynimidyl-3-maleimidopropionate (100 
eq, 0.30 mmol) and 0.17 mL TEA (400 eq, 1.2 mmol) were added. The reaction underwent at room 
temperature for 36 h under static argon atmosphere. The medium was then filtered, washed with 
DMF, MeOH and Et2O, and finally dried under vacuum. Obtained mass: 26 mg. Functionalization 
degree: 57 µmol/g (TGA); 66 µmol/g (Kaiser Test, as a difference between f-MWCNT 6 and f-
MWCNT 3). 
f-MWCNT 7: 24 mg of f-MWCNT 6 were bath-sonicated for 10 min in 25 mL of an aqueous 
solution of HCl (4M). The mixture was left stirring overnight at room temperature and subsequently 
filtered and rinsed with Milli-Q water until detecting neutral pH in the eluate. The solid cake over 
the filter membrane was rinsed with MeOH and Et2O and dried in vacuum. Obtained mass: 23 mg. 
Functionalization degree: 190 µmol/g (free amine from TGA); 56 µmol/g (Kaiser Test). 
f-MWCNT 8: 10 mg of f-MWCNT 7 (0.15 µmol of maleimide groups, estimated from Kaiser 
Test) were dispersed in 10 mL of DMF, by bath sonication for 20 min while an argon balloon was 
connected to the system. Afterwards, 5 mg of the fluorophore-labelled peptide 
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CKKSFLSPRTALINFLVK(FAM) (13.7 eq, 2.06 μmol) were added and the medium was allowed 
to react at room temperature for 2 days with constant magnetic stirring. The mixture was filtered 
and washed with DMF, Milli-Q water, MeOH, Et2O, and finally dried under vacuum. All filtrands 
were controlled by fluorescence spectroscopy in order to assure the absence of fluoresceine. 
Obtained mass: 10 mg. Functionalization degree: 35 μmol/g (TGA). 
f-MWCNT 9: 10 mg of f-MWCNT 7 (0.15 µmol of maleimide groups, estimated from Kaiser 
Test) were dispersed in 10 mL of DMF, by bath sonication for 20 min while an argon balloon was 
connected to the system. Afterwards, 4.2 mg of the peptide CKKSFLSPRTALINFLVK (13.7 eq, 
2.06 μmol) were added and the medium was allowed to react at room temperature for 2 days with 
constant magnetic stirring. The mixture was filtered and washed with DMF, Milli-Q water, MeOH, 
Et2O, and finally dried under vacuum. Obtained mass: 9 mg. Functionalization degree: 34 μmol/g 
(TGA). 
f-MWCNT 10: 9 mg of f-MWCNT 9 (0.46 μmol of free amine groups, estimated from Kaiser 
Test) were dispersed in 9 mL of anhydrous DMF through bath sonication for 20 min while keeping 
an argon balloon connected. Afterwards, 90 mg of fluoresceine isothiocyanate (FITC, 500 eq, 0.23 
mmol) and 69 μL TEA (1087 eq, 0.50 mmol) were added. The mixture was stirred at room 
temperature for two days, and then vacuum-filtered. The washing sequence was again DMF, 
MeOH, Milli-Q water and Et2O, and the product was finally dried under vacuum. The washing at 
each solvent was repeated as much as necessary until observation of no FITC fluorescent bands in 
the eluent. Obtained mass: 6 mg. 
f-MWCNT 4: 15 mg of f-MWCNT 3 were bath-sonicated for 10 min in 15 mL of an aqueous 
solution of HCl (4M). The mixture was left stirring overnight at room temperature and subsequently 
filtered and rinsed with Milli-Q water until detecting neutral pH in the filtrand. The solid cake over 
the filter membrane was rinsed with MeOH and Et2O and dried in vacuum. Obtained mass: 14 mg. 
Functionalization degree: 50 µmol/g (Kaiser Test as a difference between f-MWCNT 4 and f-
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MWCNT 3). 
f-MWCNT 5: 13 mg of f-MWCNT 4 (0.65 μmol of free amine groups, estimated from Kaiser 
Test) were dispersed in 7 mL of anhydrous DMF through bath sonication for 20 min while keeping 
an argon balloon connected. Afterwards, 25 mg of FITC (100 eq, 65 µmol) and 16 μL TEA (115 eq, 
98 µmol) were added. The mixture was stirred at room temperature for two days, and then vacuum-
filtered. The washing sequence was again DMF, Milli-Q water, MeOH, and Et2O, and the product 
was finally dried under vacuum. The washing at each solvent was repeated as much as necessary 
until observation of no FITC fluorescent bands in the filtrand. Obtained mass: 4 mg. 
Functionalization degree: 90 µmol/g (TGA); 20 μmol/g (Kaiser Test).  
The fluorescence measurements of f-MWCNT 5, 8, 10 in water are shown in Fig. S2. 
For the experiments the f-MWCNT 5, f-MWCNT 8 and f-MWCNT 10 preparations were re-
suspended in phosphate buffered saline PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM 
KH2PO4) to have 1 mg/mL of concentration. Before using they were bath-sonicated for 2 h. 
 
Yeast experiments 
Saccharomyces cerevisiae wild type (WT) strain used in these studies was the W303-1A (MAT a, 
ade2-1, can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1) rho+ 26. Cells were grown in YP complete 
medium (1% yeast extract and 1% peptone from Difco) containing 2% glucose. Viability and 
toxicity was measured calculating the growth capability of a diluted fresh culture (106 cells/mL) 
treated or not with MWCNTs. We tested 10, 20, 40, 80, 100 and 150 µg/mL from 2 h up to 72 h. 
The fluorescent signal was maintained into the cells up to 8 days of treatment; moreover the cells 
were viable and they presented buds. To visualize mitochondria, the cells were incubated with 0.5 
µM MitoTracker Red FM (Life Technologies Italy) for 15 min at room temperature or fixed with 
1% formaldehyde for 30 min at room temperature and treated with 1µg/mL of DAPI (Sigma-
Aldrich). One aliquot of the cells was fixed on glass slide and the fluorescent signal was observed 
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by Zeiss Axio Imager Z1 Fluorescence Microscope (supported by AxioVision 4.8 Digital Image 
Processing System and objective lens 63x Oil). 
 
Human monocyte experiments 
Human peripheral blood mononuclear cell cultures were prepared as follow: fresh EDTA-treated 
buffy coats from the blood of healthy donors were provided by the Transfusion Center at the 
Sapienza University of Rome in accordance with the Helsinki Declaration of 1975 and 1983. 
Monocytes were obtained from peripheral blood mononuclear cells (PBMCs). PBMCs were 
isolated by centrifugation on a LymphoprepTM density gradient. The mononuclear cells were 
washed twice with Mg2+/Ca2+-free-phosphate-buffered solution by re-suspension and centrifugation 
at 300 g at room temperature. Cells were subsequently tested for their viability by trypan blue 
exclusion and re-suspended in Roswell Park Memorial Institute (RPMI)-1640 medium, 
supplemented with 10% heat-inactivated fetal bovine serum, 2 mM glutamine, penicillin (100 
U/mL) and streptomycin (100 mg/mL). Mononuclear cells were plated in wells of tissue culture 
plates, and monocytes were obtained by selective adherence (120 min, 37°C, 5% CO2). Non-
adherent cells were removed and discarded, while the adherent cells were washed carefully twice 
with pre-warmed medium. Complete medium was then added to the plates, and the cells were 
cultured for 24 h before treatments. 
For assessing the intracellular localization of the MWCNT constructs, fluorescence microscopy 
observation was assessed. Monocytes were plated on coverslips (1 × 106 cells per coverslip), inside 
a Petri dish filled with supplemented RPMI-1640 medium and treated with f-MWCNT 5, f-
MWCNT 8, and f-MWCNT 10 at 100 µg/mL for 24 h, 48 h and 120 h. The medium was removed 
and the cells washed with fresh and pre-warmed PBS. The intracellular localization of MWCNTs 
was traced incubating the cells with the mitochondrial marker MitoTracker Red FM (Life 
Technologies Italy) at concentration of 10 nM, in growth medium without serum, at 37°C for 30 
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min. The monocytes were then washed with pre-warmed PBS and fixed in 4% paraformaldehyde 
diluted in PBS, for 10 min at room temperature. After washing several times in buffer the cells were 
examined using an Axioskop 2 Plus Microscope (supported by ZEN 2012 (blue edition) Imaging 
Software and objective lens 40x). 
Monocyte viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) from Sigma Chemicals Co. (St. Louis, MO, USA) whereas for cytotoxicity assay we used 
the LDH detection kit (lactate dehydrogenase assay) was from Roche (Roche Diagnostics, 
Indianapolis, IN, USA). In MTT assay, mt dehydrogenase enzyme of living cells converts yellow 
MTT to purple formazan, which is spectrophotometrically measured. In brief, monocytes at a 
density of 5×104 cells/well were seeded in into 96-well plates and treated with f-MWCNT 5, f-
MWCNT 8, and f-MWCNT 10 at 100 μg/mL for 24 h and 48 h. The control group was treated 
with Mg2+/Ca2+-free-phosphate-buffered solution diluted in the culture medium at the same final 
concentration used for the MWCNT constructs. Then, the medium was removed and the cells were 
incubated with MTT (0.5 mg/mL) for 4 h at 37°C. Formazan crystals in the cells were solubilized 
with 100 μL of DMSO. The level of formazan in each well was determined by measuring its 
absorbance at 570 nm. The cytotoxicity detection kit measures LDH activity released from damaged 
cells. The assay is performed in a 96-well microplate, according to the manufacturer’s instructions. 
The supernatant of each sample was incubated with tetrazolium salt 2-(p-iodophenyl)-3-(p-
nitrophenyl)-5-phenyl tetrazolium chloride (INT) to form colored formazan, a product which was 
quantitated colorimetrically. 
 
Caenorhabditis elegans assays 
The wild type Caenorhabditis elegans N2 and Escherichia coli OP50 strains (C. elegans food 
source) were used in this work according to standard protocol 27. 
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Approximately 20 young adults hermaphrodites grown at 16°C, from a synchronized culture, were 
picked onto 3.5-cm-diameter NGM (Nematode growth media) plate contained OP50 E. coli. An 
aliquot (100 µL) of 100 µg/mL nanotubes suspension, were added or not to the plates and the 
nematodes were incubated for several days at 16°C. Every day, animals were transferred to new 
plates and 100 µL of nanotubes suspensions or PBS as a control were distributed on the NGM 
plates, before nematodes seeding. Worm death was scored by the absence of touch-provoked 
movement. We observed 60 worms at each time point and repeated the experiments three times. 
After 24 h nanotubes-treatment, 1-day adult worms were allowed to lay eggs at 16°C on NGM 
supplemented with E. coli OP50. Briefly, worms were transferred onto a new bacteria plate every 
day, and the number of newly hatched larvae was counted with a Zeiss Axiovert 25 microscope 
(Thornwood, NY). This was repeated for 4 days until the mother worms stopped laying eggs. Each 
day the progeny production was recorded and was compared with the untreated controls. 
 
Statistical analysis 
Experiments were performed at least in triplicate. Data are presented as mean ± SD, and Student’s -
test or one-way ANOVA analysis coupled with a Bonferroni post test (GraphPad Prism 4.0 
software) was used to determine the statistical significance between experimental groups. Statistical 
significance was defined as ∗p < 0.05, ∗∗p< 0.01, and ∗∗∗p< 0.001. 
 
Results 
The aim of the present study is to evaluate the cellular internalization of multi-walled carbon 
nanotubes (MWCNTs) chemically conjugated or not with the peptide sequence previously 
demonstrated to suppress the defective growth phenotype due to mt tRNA mutations. Indeed studies 
on the yeast model have recently shown that overexpressed mt LeuRS-Cterm, β30_31 and β32_33 
peptides (15 and 16 amino acids long, respectively) suppressed the respiratory defects due to 
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mutations in mt tRNAs aminoacylated by class II, as well as class I mt aaRS 5,12. The suppression 
capability of these plasmid constructs was also confirmed in human cells 10,11,13. 
We treated first WT yeast cells, with three different fluorescent-labelled MWCNTs (Fig. 1). The 
preparation of the CNT derivatives started with a first cycloaddition in presence of phthalimide 
protected amino acid and paraformaldehyde (Fig. 2), followed by a second one using a Boc-
protected amino acid in order to have the orthogonal system f-MWCNT 3 to work with. This 
derivative has been fully deprotected and conjugated with FITC, to obtain the reference compound 
f-MWCNT 5. In order to introduce the selected peptide, the phthalimide was removed to expose 
amine groups, exploited to link a maleimide residue (f-MWCNT 7). Derivative f-MWCNT 7 has 
been conjugated with the fluorescently labelled peptide (f-MWCNT 8) and with the non-labelled 
sequence. For the latter, FICT has been introduced in a following step (f-MWCNT 10). 
 
Yeast Experiments 
We first studied cellular viability and toxicity; WT cells were inoculated in complete medium and 
grown overnight at 28°C. Diluted culture (106 cell/mL) was exposed to increasing amount of 
MWCNTs (as described in Experimental section) from 2 h up to 8 days. The vitality of treated cells 
showed a behaviour similar to the control in all the concentrations and time points analyzed (data 
not shown). We further evaluated the internalization of MWCNTs and localization by fluorescence 
microscopy: cells were treated with different MWCNTs concentrations at different time of 
incubation to obtain a good fluorescence signal, distinct from the naïve unstained cell populations. 
Fig. 3 shows the fluorescent signal obtained after treatment of the WT yeast cells with two different 
concentrations of the three constructs (10 µg/mL and 40 µg/mL). In this case we observed that the 
best fluorescent signal into the cells was obtained incubating the culture for 40 h. Fig. 3A shows 
that the cells treated with the f-MWCNT 5 (the vector control without the peptide sequence) have a 
diffused fluorescence, whereas in the same cells treated with the f-MWCNT 8 or f-MWCNT 10 
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separated fluorescent dots appear (Fig. 3B-C). No considerable difference of the signal is observed 
using different amounts of the peptide conjugates. 
Moreover, treatments with DAPI or MitoTracker Red and sequent co-localization of fluorescence 
show that f-MWCNT 8 and f-MWCNT 10 reached the mitochondria (Fig. 4A-B), with best co-
localization observed for the latter. This behaviour may be related with the different molecular 
structure of the constructs; in particular the f-MWCNT 8 has FITC and peptide directly linked 
whereas in the f-MWCNT 10 they are separated. The presence of the FITC on the peptide could in 
principle partially hinder the mitochondrial sequence, rendering the latter less prone to the 
recognition process. It is interesting to underline that, comparing the three pictures, the presence of 
f-MWCNT 8 and f-MWCNT 10, bearing the sequence peptide (lane 2 and 3, respectively), 
significantly induces an appreciable improvement of mitochondria localization; when the cells were 
incubated with the f-MWCNT 5 the fluorescent signal diffusely appears (lane 1). This result 
confirms that the sequence of β32_33 peptide has an intrinsic mt targeting activity. 
 
Monocyte cytotoxicity assessment in vitro 
Human monocytes and macrophages are cells known to be involved in both the innate and adaptive 
immune responses, the role of which is equally fundamental in the initiation, maintenance and 
resolution of inflammatory processes. For this purpose, we tested circulating monocytes, because 
they represent the first line of defense in the immune response to foreign materials, including 
nanostructures in general. Thus they are of particular relevance in the investigation of the cell 
ability to internalize foreign body materials and of the toxic/proinflammatory potential of the 
materials. 
The in vitro viability of PBMCs (Peripheral blood mononuclear cells) exposed to MWCNTs 
conjugates was tested by different approaches (Fig. 5): checking the release of the cytosolic enzyme 
lactate dehydrogenase (LDH) by using a LDH diagnostic kit; and the possible effect on the cell mt 
17 
 
function by the MTT test. The measurement of LDH in the cell culture supernatants after 24 h and 
48 h indicates no significant increase of LDH levels when the cells were exposed to f-MWCNT 5, 
f-MWCNT 8 and f -MWCNT 10, indicating a negligible cytotoxicity of these substrates on 
PBMCs (Fig. 5A). The MTT test further confirmed PBMC viability, showing that the conjugates do 
not affect cell mt function (Fig. 5B). 
 
Monocyte microscopy 
We further evaluated the internalization of fluorescently-labelled MWCNTs and localization by 
fluorescence microscopy after 24 h, 48 h and 120 h of treatment with 100 μg/mL of constructs (Fig. 
6). Since the time of treatment did not change the fluorescence intensity, we show a choice of 
pictures as example (Fig. 6). We observed that the PBMCs treated with the f-MWCNT 5 (the 
vector control without the peptide sequence) for 24 h and 48 h have a diffused fluorescence (Fig. 
6A), whereas in the same cells treated with f-MWCNT 8 or f-MWCNT 10 a separated fluorescent 
dots appear (Fig. 6B-C). After 24 h of treatment the MWCNTs were internalized; after 48 h and 
120 h of incubation it was possible to find higher number of fluorescent nanotubes into the cells. 
Treatment with MitoTracker Red and sequent co-localization of fluorescence shows that the best 
result is observed when the cells were incubated for longer times with MWCNTs (48 h and 120 h). 
As previously observed for the yeast cells, the best co-localization between the mt signal and the 
MWCNTs is obtained when the peptide sequence is present, especially in the case of f-MWCNT 10 
construct (Fig. 6C). These results demonstrate that mt targeting activity of the β32_33 peptide is 
optimized when this peptide is not bound to the FITC. 
 
Longevity and genotoxicity of Caenorhabditis elegans exposed to CNTs 
In order to evaluate the in vivo toxicity of these nanostructures, the nematode Caenorhabditis 
elegans, a well-established model system in nanotoxicology, was used 28. We first analyzed the 
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effects of nanotubes on the worm longevity. A population of 1-day adult hermaphrodites was 
transferred on NGM E. coli OP50 plates on which 100 μL of nanotube suspensions (100 µg/mL) 
was distributed, before nematodes seeding. Afterward, the viability was examined with respect to 
untreated animals (Fig. 7A). The life-span showed no significant differences between the worms 
treated with the two peptide-conjugated nanotubes (f-MWCNT 8 and f-MWCNT 10) and the 
control, meanwhile the nanotube f-MWCNT 5 induced a slight decrease in the survival. 
To deeper investigate nanostructures bioassessment, we also analyzed C. elegans reproductive 
potential as an indicator of genotoxicity. Hence, a brood size assay for animals exposed every day 
to the nanotubes was performed. The progeny production of worms exposed to FITC-conjugated 
nanotubes with or without the peptide was almost identical to the untreated controls (Fig. 7B).  
 
Discussion 
Overexpression of the oligonucleotide sequences coding for the peptides β30_31 
(MAVLINNKACGKIPV) or β32_33 (KKSFLSPRTALINFLV), comprised within the orthologous 
carboxy-terminal domain of human LeuRS, corrected the defects associated with several point 
mutations in yeast mt tRNA 5,12. This activity has been obtained also in transfected cybrid lines 
bearing substitution in tRNALeu(UUR) and tRNALys 13. 
In view of potential therapeutic applications, a suitable carrier is necessary since peptides are 
unlikely to pass cell and mt membranes and to possess satisfactory bioavailability properties.  
Nanotechnology based delivery vehicles provide numerous advantages to increase the therapeutic 
activities of small molecules, usually conferring them a better pharmacokinetics. Moreover, 
nanovehicles can be modified to target specific cells or organelles in order to carry the drug to the 
effective site of action. It is accepted that to deliver molecules inside the mt matrix and to have 
spatio-temporal control over drug release in different mt compartments, nanoparticles need to be 
engineered with precise size, lipophilic surface, appropriate charge, and specific targeting moieties 
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on the surface. Moreover requirements of biocompatibily and biodegradability of the materials are 
necessary to envision potential in vivo uses of those platforms. 
Currently described methods for mt gene therapy are allotropic genes, importable tRNAs, anti-
genome agents, liposomes and ions, RNA transporters 29.  
The applicability of these interesting approaches in vivo remains to be determined and there are 
problems related to the uptake and localization of these artificial compounds, and evidence for 
functional delivery of DNA is lacking. 
It should be noted that up to now none method has the demonstrated capability to cure mt diseases 
and successful gene replacement within mitochondria through homologous recombination has not 
been obtained yet. Therefore, non-viral vectors technique and new selective treatments to deliver 
molecules directly to mitochondria should be developed. 
Several studies investigated the possibility of using mitochondria-targeted micelles, dendrimers and 
other materials 30,31. For example liposomes emerged as promising mitochondria delivery system in 
fact they were found to co-localize with MitoTracker Red in mitochondria, however size and 
polydispersity are the drawbacks of this technology 32.  
Among the numerous types of nanocarriers proposed since now, carbon nanotubes are emerging as 
possible delivery system.  
Recently it has been reported that MWCNTs conjugated to a mitochondria targeting peptide 
sequence (KMSVLTPLLRGLTGSARRLPVPRAKC) exhibited high level of nanotube 
accumulation in mitochondria of macrophages and HeLa cells without showing any significant 
cytotoxicity 21. 
Our results indicate that the peptide sequence originally identified to have intrinsic mt targeting 
activity when overexpressed by plasmid in yeast and cybrid cells 5,12,13 has similar property when 
conjugated to MWCNTs. In fact, f-MWCNT 10 bearing peptide CKKSFLSPRTALINFLVK (Fig. 
1), significantly improves the mt co-localization of FITC and mt fluorescence signals with respect 
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to f-MWCNT 8 and, especially, to f-MWCNT 5 (Fig. 4 and 6). This improvement is highlighted 
by merged fluorescent dots, that have been previously observed for mitochondria-targeting 
MWCNT constructs 21, 22. 
Moreover, we have demonstrated that the compounds here studied do not affect cellular viability 
and cytotoxicity both in vitro and in vivo also utilizing the simple pluricellular model C. elegans. 
Various special features such as its well characterized genome, genetic manipulability, easy of 
maintenance, short life cycle, transparent body with small size, etc. have led to an extensively use of 
the nematode to investigate the toxicity of nanomaterials 33,34. Moreover, many of the basic 
physiological processes and stress responses that are observed in higher organisms (e.g., humans) 
are conserved in C. elegans. Our data indicated that the all the analyzed constructs did not affect the 
life-span, the brood size and the reproductive potential of the nematodes although the FITC-
conjugate (f-MWCNT 5) slightly decreased the survival of the animals (Fig. 7). It has been 
reported that MWCNTs exposure can produced damage in C. elegans on the functions of both 
primary and secondary targeted organs and that MWCNTs could be translocated into the secondary 
targeted organs such as reproductive organs 35,36. However, it should be taken into account the 
different size, shape, and surface functionality of the several MWCNTs tested, reflecting different 
degrees of toxicity. 
Overall, f-MWCNT 10 can be considered a good nanoplatform for delivering of bioactive 
molecules and treating mt tRNAs deficiencies, although for its further development as drug delivery 
agent will be necessary to investigate the efficacy of the construct in cell lines bearing mt 
dysfunctions. 
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Legends 
Fig. 1 Scheme of the three MWCNTs constructs described into this paper. f-MWCNT 8, f-
MWCNT 10 and f-MWCNT 5, presenting respectively peptide and FITC bound to the same 
functional groups (f-MWCNT 8), peptide and FITC bound to different groups of the tubes (f-
MWCNT 10) and only the FITC (f-MWCNT 5). 
 
Fig. 2 Synthesis scheme of f-MWCNT 5, f-MWCNT 8 and f-MWCNT 10 (in blue colour). 
 
Fig. 3 Internalization of fluorescent signal of the MWCNTs constructs in S. cerevisiae. The WT 
yeast cells were incubated in YP liquid medium contained 2% of glucose at 28°C with 10 µg/mL or 
40 µg/mL of f-MWCNT 5 (A), f-MWCNT 8 (B) or f-MWCNT 10 (C). After treating the cells 
were observed by fluorescence microscopy. Scale bar corresponds to 1 µm. 
 
Fig. 4 Co-localization of fluorescent signals with mitochondria of S. cerevisiae. WT yeast cells 
were incubated in YP liquid medium contained 2% of glucose at 28°C with 20 µg/mL of f-
MWCNT 5 (lane 1), f-MWCNT 8 (lane 2) or f-MWCNT 10 (lane 3). Before fluorescence 
microscopy the same aliquot of each treated culture was stained with DAPI (A) or MitoTracker Red 
(B) to visualize the mitochondria. Scale bar corresponds to 1 µm. 
 
Fig. 5 Effect of the three MWCNTs constructs on Human monocytes cell viability and LDH release. 
Human monocytes were treated with 100 μg/mL of f-MWCNT 5, f-MWCNT 8 or f-MWCNT 10 
for 24 h and 48 h. The cell viability was assessed by MTT reduction assay (A) and LDH release 
assay (B). Values are expressed as mean ± S.D. (n=3). 
 
27 
 
Fig. 6 Co-localization of fluorescent signals with mitochondria of Human monocytes. Human 
monocytes were incubated with 100 μg/mL of f-MWCNT 5 (A), f-MWCNT 8 (B) or f-MWCNT 
10 (C) for 24 h, 48 h and 120 h. After treating the cells were stained with MitoTracker Red, fixed in 
4% paraformaldehyde and observed by fluorescence microscopy. Scale bar corresponds to 10 µm. 
 
Fig. 7 Evaluation of MWCNTs toxicity in C. elegans: effect of nanotubes on nematode lifespan and 
fertility. (A) Kaplan-Meier survival plot of N2 worms untreated or treated with FITC-conjugated 
nanotubes with (f-MWCNT 8 and f-MWCNT 10) or without (f-MWCNT 5) the peptide; n= 60 for 
each data point of single experiments. (B) Average embryos production per worm in the presence of 
the three different nanomaterials. Untreated animals are reported as controls. Bars represent the 
mean of three independent experiments. 
 
